투자판단관련주요경영사항 (COVID-19 예방 백신 AdCLD-CoV19-1 LP.8.1의 제2상 임상시험 계획 승인(IND) 신청 반려)[코]
Received: 5/8/2026 · Reporter: 셀리드
셀리드는 COVID-19 예방 백신 AdCLD-CoV19-1 LP.8.1의 제2상 임상시험 계획 승인(IND) 신청이 반려되었다고 공시하였다.
🏢 Past 12 months filing pattern (this company)
- Total filings
- 32 filings
- Same category
- 20 filings
- Previous same-category filing
- 8/6/2026
- Corrections / withdrawals
- 3 filings
Filing source / License
The original PDF/HTML of this filing is provided by FSS DART. MarketBubbles displays only metadata (title, receipt number, type, reporter) and a rule-based summary; we do not mirror the original PDF body (per FSS ToS).